DNSP-11 (Peptide) – Product Details

DNSP 11 is a dopamine-neuron dopamine-stimulating peptide that has the potential to affect dopamine release, neuron function, and metabolite tissue levels. By activating dopamine neurons and dopaminergic pathways, DNSP 11 may improve neuronal cell health and cognitive function. Studies with normal adult rats resulted in significant improvement in common behavioral measures related to neurodegenerative disorders. The mechanism of action likely involves rapid uptake, dopamine turnover, receptor activation, and downstream signaling pathways like the GDNF family receptor or neurotrophic factors like brain-derived neurotrophic factor.  

Key benefits observed so far include increased striatal dopamine content, potassium-evoked dopamine release, and improvement in apomorphine-induced rotational behavior. Further research is still needed and DNSP 11 is currently intended only for laboratory and research purposes. It is not approved for human consumption.

• CAS Number: 616204-22-9
• Molar Mass: 1180.27 g/mol
• The chemical formula: C50H81N15O18
• IUPAC Name: acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
• Also known by Synonyms: 10-des-Gly,6-(D-Ala)-LHRH ethylamide, acetate salt, 6-D-Ala-10-D-Gly-LHRH-ethylamide, Ala(6)-Gly(10)-GnRH, GnRHa cpd, LHRH, Ala(6)-Gly(10)-ethylamide, LHRH, alanine(6)-glycine(10)-ethylamide-

What is DNSP 11?

Dopamine Neuron Stimulating Peptide 11 (DNSP 11) is a novel peptide that has garnered significant attention in the field of neurodegenerative diseases, particularly in the context of Parkinson’s disease (PD) research. Utilizing rat models and non-human primates, studies have explored the effects of DNSP 11 on various aspects of the dopaminergic system. Investigations into its impact on drug targets, such as tyrosine hydroxylase and receptor tyrosine kinase, have revealed promising outcomes in terms of neuronal survival and motor symptom alleviation.

In animal model studies, DNSP 11 has demonstrated its potential therapeutic value in addressing motor impairment associated with PD. Particularly in aged rhesus monkeys, the peptide’s effects on dopamine turnover and substantia nigra pars compacta (the source of the important nigrostriatal dopamine pathway) have shown a significant improvement, as observed through high-speed chronoamperometry and apomorphine-induced rotational behavior studies.

The peptide’s tissue distribution within the central nervous system, including its rapid uptake and influence on various brain regions, has been a focal point in understanding its mechanism of action. DNSP 11’s ability to affect dopamine release, cognitive function, and normal striatal dopamine content highlights its relevance for research purposes, both in laboratory settings and clinical trials.

Notably, DNSP 11 has exhibited neurotrophic factor-like properties, influencing gene expression and promoting the growth of dopaminergic neurons. Studies employing Schwann cells and glial cell line-derived neurotrophic factor (GDNF) treatment have indicated its potential role in supporting neuron function and survival. The blood-brain barrier penetration of DNSP 11 further suggests its applicability in addressing neurodegenerative disorders.

Potential Applications of DNSP-11

Potential treatment of Parkinson’s Disease (PD)

A particular study examined the potential effects of DNSP-11 on hemiparkinsonism induced by MPTP in awake rhesus macaques (monkeys), utilizing a gradual dosage approach. Over ten weeks, the macaque models received repeated intranasal doses, and at the tested DNSP-11 concentrations, no discernible side effects were observed. Following a single bilateral intranasal dosage, the animals displayed possibly enhanced fine motor skills in both limbs, altered dopamine levels in brain tissue, and extensive DNSP-11 distribution throughout the central nervous system and cerebrospinal fluid. These results imply that in a non-human primate model of Parkinson’s disease, repeated intranasal administration of DNSP-11 potentially improves motor function and modifies brain chemistry. [R]

DNSP-11 was given to normal rat models through their noses over 3 weeks. Higher doses of 300 micrograms caused an increase in dopamine activity in parts of the brain that control movement. This suggests that DNSP-11 may stimulate the dopamine system. [R]

DNSP-11 was also given to rat models through their noses with a type of brain damage seen in Parkinson’s disease. It had protective effects: less amphetamine-induced movement problems; decreased dopamine turnover in damaged areas; and more survival of dopamine-producing brain cells.  Finally, traced DNSP-11 was seen to spread quickly throughout the brain after a single nose dose. It reached movement-control areas in as little as 30 minutes. [R]

Potential to Increase Dopamine Turnover

Recent studies have shown that DNSP-11, a peptide derived from the glial cell line-derived neurotrophic factor (GDNF) proregion, may influence the nervous system. Using high-speed chronoamperometry, researchers investigated the effects of DNSP-11 treatment on dopamine release patterns in the rat striatum over time. They found that two weeks of DNSP-11 treatment may lead to elevated dopamine release in the striatum compared to baseline, suggesting a localized effect of DNSP-11 to increase dopamine signaling in this brain region critical for motor control and reward processing. [R]

While promising, additional research is required to fully understand the mechanisms and implications of how DNSP-11 influences dopamine neuron function and release dynamics. Future studies should investigate if the elevated dopamine levels persist with sustained DNSP-11 administration, examine impacts on dopamine-associated behaviors, and explore the receptors and signaling pathways involved to elucidate the neurological effects of this GDNF-derived peptide. [R]

Expanding this work could provide key insights into developing DNSP-11 as a potential therapeutic agent for disorders involving dopamine dysfunction, such as Parkinson’s disease or addiction. [R]

How Does DNSP 11 Work?

DNSP 11 is a cell line-derived neurotrophic factor that has potential dopamine neuron-stimulating actions when used for laboratory and research purposes. Studies administering DNSP 11 to normal adult rats resulted in effects on dopamine neurons, dopamine metabolite tissue levels, and dopaminergic neurons in the central dopamine system. The ability of DNSP 11 to affect dopamine release was measured in neuronal cells using techniques like high-performance liquid chromatography. [R]

DNSP 11 acts similarly to other neurotrophic factors like brain-derived neurotrophic factor and nerve growth factor. It appears to support dopamine neuron function and survival of dopamine neurons that degenerate in the substantia nigra pars compacta region in Parkinson’s disease models. Increased uptake and tissue levels of DNSP 11 led to increased dopamine and dopamine release in normal rat striatum. This could translate to functional effects in Parkinson’s disease participants where there is dopamine depletion. [R]

More research is still needed in both laboratory and research use of DNSP 11 as well as testing in animal models and Parkinson’s disease participants. However, the initial results show promise that DNSP 11 may promote neuronal survival and protect diseased neurons in affected brain regions. If shown to cross the brain barrier when administered in peptide form, DNSP 11 could influence gene expression and act directly on the dopaminergic system and neuron function. This neurotrophic factor may ultimately have therapeutic utility in PD research and treatment of motor symptoms. [R]

Safety and Side Effects 

Animal studies so far have not resulted in noteworthy adverse events, however, more research is still needed before drawing definitive conclusions. As with any peptide or protein introduced to biological systems, the potential exists for immunogenic reactions which would need to be evaluated. Overall the early data appears promising for DNSP 11 having an acceptable safety profile but further studies, particularly long-term effects, are still required.

Frequently Asked Questions

What is DNSP-11? 

DNSP11 is a peptide that has the potential to stimulate dopamine neuron function and increase dopamine release in the brain. It has potential therapeutic applications for treating Parkinson’s disease and other dopamine-related disorders.

Is DNSP-11 safe?

Safety studies so far in animal models have not resulted in any significant adverse effects even with repeated high dosages. More studies are still needed, especially assessing long-term safety and human trials, before definitive safety conclusions can be made. 

While quite reassuring for further development of DNSP 11, longer-term preclinical studies focused on chronic toxicology, reproductive toxicity, genotoxicity, and carcinogenicity are still needed to substantiate these preliminary safety indications, along with eventual human clinical trials. Specific areas still requiring deeper evaluation include defining a maximum acceptable dose level, fully elucidating the mechanisms of clearance from the body, establishing if there are risks for tissue bioaccumulation over months or years of exposure, and ruling out late-onset or delayed adverse reactions.

Fully investigating the safety profile in both healthy subjects and Parkinson’s disease participants with inherent neurological deficits will be crucial.

Is DNSP-11 approved for medical use? 

At this time, DNSP 11 remains an investigative compound that has not been approved by global regulatory bodies for clinical use as a biologic or compound. It would require the successful completion of multiple phases of clinical trials demonstrating both safety and efficacy in humans related to specific medical conditions before DNSP 11 could achieve approved status. Currently, DNSP 11 is still in the preclinical stages of testing, focused on studies in cell cultures and animal models to establish initial proof-of-concept results and pave the way toward trials in human test subjects.

These preclinical experiments have included assessments of impacts on dopamine neuron stimulation, degree of dopamine release modulation, optimal dosage ranges, treatment duration effects, associated behavior changes, and initial safety indications.

Why Buy DNSP-11 from BehemothLabz?

Behemoth Labz is the best place to purchase DNSP-11 online.

We have been around since 2014, supplying the highest-quality research compounds money can buy. All of our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee on DNSP 11.

Summary

DNSP 11 is a Dopamine Neuron Stimulating Peptide that affects dopamine release and dopamine neuron function. Studies in normal adult rat models resulted in significant improvement in dopamine metabolite tissue levels, as well as increased dopamine turnover and potassium-evoked DA release. Further research suggests that DNSP 11’s dopamine neuron stimulating actions may have therapeutic potential for neurodegenerative disorders like Parkinson’s disease.

Animal models indicate DNSP 11 can cross the blood-brain barrier, increase neuronal survival and growth factor production from glial cells, improve cognitive function and common behavioral measures like apomorphine-induced rotational behavior, stimulate rapid uptake and high levels of dopamine in striatal dopamine content, and regulate gene expression of dopamine depletion and other receptor tyrosine kinases.

DNSP 11 shows promise for laboratory and research use, including high-performance liquid chromatography, in cell line-derived and tissue distribution studies on dopaminergic neurons and biological systems related to Parkinson’s disease participants, neurotrophic factors like nerve growth factor and brain-derived neurotrophic factor, and motor symptoms.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions and please familiarize yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at support@behemothlabz.com if you are not fully satisfied with the product. Customer satisfaction is our number one priority!

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Strength	5mg

1st Party COA